Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

DISEASE CHARACTERISTICS: * Histologically confirmed solid tumors potentially expressing mutant ras, including colon, lung, pancreas, thyroid, endometrial, head and neck, testicular, hepatocellular, and melanoma * Ras mutations must be one of the following point mutations at codon 12: * Glycine to cysteine * Glycine to aspartic acid * Glycine to valine * Metastatic disease for which no known chemotherapy or radiotherapy would increase survival * Tumor tissue must be available for determination of ras mutation * No prior CNS metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-1 Life expectancy: * More than 3 months Hematopoietic: * WBC at least 2,000/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 2.0 mg/dL * SGOT/SGPT no greater than 4 times normal * No hepatitis B or C infection Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * No active ischemic heart disease (New York Heart Association class III or IV) * No myocardial infarction within the past 6 months * No history of congestive heart failure, ventricular arrhythmias, or other arrhythmias requiring therapy Immunologic: * No prior allergy to eggs * No prior autoimmune disease, including the following: * Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia * Systemic lupus erythematosus, Sjogren's syndrome, or scleroderma * Myasthenia gravis * Goodpasture syndrome * Addison's disease, Hashimoto's thyr…